Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIM-DJ2727 FMT in HIV-infected MSM on ART
NCT03329560Phase 1Completed
- Sponsor
- UTHealth Houston
- Start
- Apr 2018
- Primary completion
- Oct 2019
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of PRIM-DJ2727 in human immunodeficiency virus infection (HIV), sponsored by UTHealth Houston. Primary endpoint: Number of participants with adverse events related to study drug at 52 weeks. Started Apr 2018; status: completed.
02
Drugs
PRIM-DJ2727
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03329560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03329560.